Bangladesh captain Mominul Haque believes his team are well prepared ahead of the first Test against South Africa starting at Kingsmead on Thursday.
Speaking at a pre-match press conference, Mominul said: "South Africa are playing at home and that is always an advantage. However, we have been here for nearly three weeks and the boys have adjusted to conditions."
Mominul and the other Test specialists had a training camp at former South African player and coach Gary Kirsten's academy in Cape Town, while the one-day side were pulling off an historic series win against South Africa.
Bangladesh have lost all six Tests on three previous tours of South Africa and Kingsmead is an unknown factor for the current players, with Bangladesh having only once at the ground, when they lost to Canada in the 2003 Cricket World Cup.
Mominul said he was not sure how the pitch would play.
"There's not too much point in thinking too much about the wicket. It could aid the pacers but still be good for batting. Spinners may come into play as the match progresses."
Unlike on previous tours, Bangladesh will be looking to match South Africa with their fast bowlers.
Ebadot Hossain was the man of the match when they won a Test in New Zealand in January, while Taskin Ahmed was the player of the ODI series against South Africa.
"The pace bowlers have been doing very well in recent times," said Mominul. "They have a lot of confidence coming into this Test series and the whole team has confidence in them."
South African left-arm spinner Keshav Maharaj, who plays his domestic cricket at Kingsmead, said earlier he was not sure how the pitch would play, with more grass on the surface than usual.
"I haven't seen Kingsmead with the colour of the grass like this," he said. "It's a relaid surface." But he said he expected it to be a "traditional" first-class pitch.
With South Africa's first-choice fast bowlers playing in the Indian Premier League, Maharaj is by a distance the most experienced Test bowler in the squad.
But he said he was confident that the replacement pace bowlers would be able to challenge the Bangladesh batsmen.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.